Trexquant Investment LP Takes $2.75 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Trexquant Investment LP acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 107,147 shares of the company's stock, valued at approximately $2,754,000. Trexquant Investment LP owned 0.12% of IDEAYA Biosciences as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of IDEAYA Biosciences by 2.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,496 shares of the company's stock worth $10,090,000 after purchasing an additional 6,219 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of IDEAYA Biosciences in the third quarter valued at $246,000. State Street Corp lifted its position in shares of IDEAYA Biosciences by 15.4% during the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company's stock valued at $105,112,000 after acquiring an additional 443,640 shares during the last quarter. Two Sigma Advisers LP grew its holdings in shares of IDEAYA Biosciences by 1.7% in the 3rd quarter. Two Sigma Advisers LP now owns 468,100 shares of the company's stock worth $14,829,000 after acquiring an additional 7,700 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of IDEAYA Biosciences during the third quarter worth $245,000. 98.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IDYA has been the topic of a number of research analyst reports. Wedbush reaffirmed an "outperform" rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Stephens reiterated an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $53.58.

IDEAYA Biosciences Stock Up 6.2 %

IDYA stock traded up $0.98 during mid-day trading on Friday, reaching $16.75. 1,555,053 shares of the stock traded hands, compared to its average volume of 924,816. The business has a 50-day moving average of $18.86 and a two-hundred day moving average of $24.30. The firm has a market capitalization of $1.47 billion, a PE ratio of -5.08 and a beta of 0.51. IDEAYA Biosciences, Inc. has a 52 week low of $13.45 and a 52 week high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million. On average, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.